Literature DB >> 20831193

Quantitative structure activity relationship for inhibition of human organic cation/carnitine transporter.

Lei Diao1, Sean Ekins, James E Polli.   

Abstract

Organic cation/carnitine transporter (OCTN2; SLC22A5) is an important transporter for L-carnitine homeostasis, but can be inhibited by drugs, which may cause L-carnitine deficiency and possibly other OCTN2-mediated drug-drug interactions. One objective was to develop a quantitative structure-activity relationship (QSAR) of OCTN2 inhibitors, in order to predict and identify other potential OCTN2 inhibitors and infer potential clinical interactions. A second objective was to assess two high renal clearance drugs that interact with OCTN2 in vitro (cetirizine and cephaloridine) for possible OCTN2-mediated drug-drug interactions. Using previously generated in vitro data of 22 drugs, a 3D quantitative pharmacophore model and a Bayesian machine learning model were developed. The four pharmacophore features include two hydrophobic groups, one hydrogen-bond acceptor, and one positive ionizable center. The Bayesian machine learning model was developed using simple interpretable descriptors and function class fingerprints of maximum diameter 6 (FCFP_6). An external test set of 27 molecules, including 15 newly identified OCTN2 inhibitors, and a literature test set of 22 molecules were used to validate both models. The computational models afforded good capability to identify structurally diverse OCTN2 inhibitors, providing a valuable tool to predict new inhibitors efficiently. Inhibition results confirmed our previously observed association between rhabdomyolysis and C(max)/K(i) ratio. The two high renal clearance drugs cetirizine and cephaloridine were found not to be OCTN2 substrates, and their diminished elimination by other drugs is concluded not to be mediated by OCTN2.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20831193      PMCID: PMC2997942          DOI: 10.1021/mp100226q

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  35 in total

1.  beta-lactam antibiotics as substrates for OCTN2, an organic cation/carnitine transporter.

Authors:  M E Ganapathy; W Huang; D P Rajan; A L Carter; M Sugawara; K Iseki; F H Leibach; V Ganapathy
Journal:  J Biol Chem       Date:  2000-01-21       Impact factor: 5.157

2.  Organic cation/carnitine transporter OCTN2 (Slc22a5) is responsible for carnitine transport across apical membranes of small intestinal epithelial cells in mouse.

Authors:  Yukio Kato; Mikihiro Sugiura; Tomoko Sugiura; Tomohiko Wakayama; Yoshiyuki Kubo; Daisuke Kobayashi; Yoshimichi Sai; Ikumi Tamai; Shoichi Iseki; Akira Tsuji
Journal:  Mol Pharmacol       Date:  2006-06-05       Impact factor: 4.436

Review 3.  Cheminformatics analysis and learning in a data pipelining environment.

Authors:  Moises Hassan; Robert D Brown; Shikha Varma-O'brien; David Rogers
Journal:  Mol Divers       Date:  2006-09-22       Impact factor: 2.943

4.  OCTN2-mediated carnitine uptake in a newly discovered human proximal tubule cell line (Caki-1).

Authors:  Natalie Glube; Ellen Closs; Peter Langguth
Journal:  Mol Pharm       Date:  2007 Jan-Feb       Impact factor: 4.939

5.  Integrated in silico-in vitro strategy for addressing cytochrome P450 3A4 time-dependent inhibition.

Authors:  Michael Zientek; Chad Stoner; Robyn Ayscue; Jacquelyn Klug-McLeod; Ying Jiang; Michael West; Claire Collins; Sean Ekins
Journal:  Chem Res Toxicol       Date:  2010-03-15       Impact factor: 3.739

6.  Rapid identification of P-glycoprotein substrates and inhibitors.

Authors:  Cheng Chang; Praveen M Bahadduri; James E Polli; Peter W Swaan; Sean Ekins
Journal:  Drug Metab Dispos       Date:  2006-09-22       Impact factor: 3.922

7.  Functional and pharmacological characterization of human Na(+)-carnitine cotransporter hOCTN2.

Authors:  C A Wagner; U Lükewille; S Kaltenbach; I Moschen; A Bröer; T Risler; S Bröer; F Lang
Journal:  Am J Physiol Renal Physiol       Date:  2000-09

8.  A combined approach to drug metabolism and toxicity assessment.

Authors:  Sean Ekins; Sergey Andreyev; Andy Ryabov; Eugene Kirillov; Eugene A Rakhmatulin; Svetlana Sorokina; Andrej Bugrim; Tatiana Nikolskaya
Journal:  Drug Metab Dispos       Date:  2005-12-28       Impact factor: 3.922

9.  Uptake of cardiovascular drugs into the human heart: expression, regulation, and function of the carnitine transporter OCTN2 (SLC22A5).

Authors:  Markus Grube; Henriette E U Meyer zu Schwabedissen; Damaris Präger; Jeanette Haney; Klaus-Uwe Möritz; Konrad Meissner; Dieter Rosskopf; Lothar Eckel; Michael Böhm; Gabriele Jedlitschky; Heyo K Kroemer
Journal:  Circulation       Date:  2006-02-20       Impact factor: 29.690

10.  Urinary excretion of carnitine as a marker of proximal tubular damage associated with platin-based antineoplastic drugs.

Authors:  Manuel Haschke; Tanja Vitins; Saskia Lüde; Liliane Todesco; Katerina Novakova; Richard Herrmann; Stephan Krähenbühl
Journal:  Nephrol Dial Transplant       Date:  2009-09-07       Impact factor: 5.992

View more
  10 in total

1.  Making Transporter Models for Drug-Drug Interaction Prediction Mobile.

Authors:  Sean Ekins; Alex M Clark; Stephen H Wright
Journal:  Drug Metab Dispos       Date:  2015-07-21       Impact factor: 3.922

Review 2.  The Next Era: Deep Learning in Pharmaceutical Research.

Authors:  Sean Ekins
Journal:  Pharm Res       Date:  2016-09-06       Impact factor: 4.200

3.  Comparison of Deep Learning With Multiple Machine Learning Methods and Metrics Using Diverse Drug Discovery Data Sets.

Authors:  Alexandru Korotcov; Valery Tkachenko; Daniel P Russo; Sean Ekins
Journal:  Mol Pharm       Date:  2017-11-13       Impact factor: 4.939

4.  Computational modeling to accelerate the identification of substrates and inhibitors for transporters that affect drug disposition.

Authors:  S Ekins; J E Polli; P W Swaan; S H Wright
Journal:  Clin Pharmacol Ther       Date:  2012-09-26       Impact factor: 6.875

5.  A substrate pharmacophore for the human organic cation/carnitine transporter identifies compounds associated with rhabdomyolysis.

Authors:  Sean Ekins; Lei Diao; James E Polli
Journal:  Mol Pharm       Date:  2012-02-28       Impact factor: 4.939

6.  Molecular determinants of ligand selectivity for the human multidrug and toxin extruder proteins MATE1 and MATE2-K.

Authors:  Bethzaida Astorga; Sean Ekins; Mark Morales; Stephen H Wright
Journal:  J Pharmacol Exp Ther       Date:  2012-03-14       Impact factor: 4.030

7.  Repurposing Approved Drugs as Inhibitors of Kv7.1 and Nav1.8 to Treat Pitt Hopkins Syndrome.

Authors:  Sean Ekins; Jacob Gerlach; Kimberley M Zorn; Brett M Antonio; Zhixin Lin; Aaron Gerlach
Journal:  Pharm Res       Date:  2019-07-22       Impact factor: 4.200

8.  A common feature pharmacophore for FDA-approved drugs inhibiting the Ebola virus.

Authors:  Sean Ekins; Joel S Freundlich; Megan Coffee
Journal:  F1000Res       Date:  2014-11-14

9.  Open Source Bayesian Models. 3. Composite Models for Prediction of Binned Responses.

Authors:  Alex M Clark; Krishna Dole; Sean Ekins
Journal:  J Chem Inf Model       Date:  2016-01-19       Impact factor: 4.956

10.  Autophagic flux inhibition and lysosomogenesis ensuing cellular capture and retention of the cationic drug quinacrine in murine models.

Authors:  Alexandre Parks; Xavier Charest-Morin; Michael Boivin-Welch; Johanne Bouthillier; Francois Marceau
Journal:  PeerJ       Date:  2015-10-06       Impact factor: 2.984

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.